ICV Philadelphia will connect Investors with Key Opinion Leaders from Thomas Jefferson University, Academia and Senior Management from a select group of companies in a collaborative environment to share ideas, evaluate opportunities, and identify ways in which the allocation of capital can create a social impact beyond a financial return.

 

Innovative research is leading to breakthroughs in medicines, therapies, devices, and technologies which will define the future of healthcare. There will be new treatments capable of curing a myriad of illnesses, thus helping people to live longer, with less pain. If we invest wisely many will enjoy a better quality of life.

Investment Community Visibility (ICV) is building a community of extraordinary individuals, who, by virtue of their wealth, knowledge and caring, can advance corporate responsibility, capitalize businesses at significant levels, and influence systemic change in the world.

ICV Philadelphia will present opportunities for positive change.
 

Where is Healthcare in 2030?
  • Alfonso Chang, Managing Director of Relativity Healthcare Partners, an an investment group dedicated to providing growth capital to emerging healthcare companies.
  • David Nikodem, is Managing Director and Head of Biopharma Investments of Ally Bridge Group, a global healthcare-focused, multi-strategy investment group with a portfolio of healthcare investments in China, the US and Europe, and of Themes Investment Partners, a China-focused private equity fund. In 2015, Ally Bridge Group, in close collaboration with Wuxi’s founder/chairman/CEO, initiated, led and completed the landmark USD3.3 billion take-private of Wuxi Pharmatech, a leading global life science service company.
  • Greg Simon is the Director of the Biden Cancer Initiative at the Biden Foundation and the former Executive Director of the White House Cancer Moonshot Task Force, a position created by President Barack Obama and for which he was chosen by Vice President Joe Biden in March 2016. As Executive Director, Greg assembled and led a team of eight professionals to support the work of the Vice President in developing and promoting the goals of the Cancer Moonshot in numerous meetings and presentations and to coordinate the work of the Task Force comprised of twenty cabinet and sub-cabinet offices. Over the past nine months Greg and his team worked across the Task Force, academia and the private sector to create over seventy innovative collaborations. On October 17th, 2016, Greg joined the Vice President to present the Cancer Moonshot reports to President Obama in an Oval Office briefing. On December 7, 2016, the passage of the 21st Century Cures Act provided $1.8 billion for the Cancer Moonshot over the next seven years.
Can We Cure Cancer In Our Lifetime?

The three of the most dreaded words in any language are “You have cancer”. Sadly, these words are repeated to stunned patients and their families every day. Through innovative research and collaborative inter-disciplinary teams, significant breakthroughs have been made in reducing mortality rates and increasing life expectancy. Unthinkable only a short time ago, the prospect that cancer may be curable has increasingly become part of the conversation.

  • Karen Knudsen, PhD, is Director of the Sidney Kimmel Cancer Center at Thomas Jefferson University and the Hilary Koprowski Chair of the Department of Cancer Biology of the Sidney Kimmel Medical College of Thomas Jefferson University. Jefferson has been a Philadelphia area leader in oncology research, patient treatment and cancer education services for almost 25 years. Initially a single cancer center with a staff of 30, today the Sidney Kimmel Cancer Center (SKCC) at Jefferson includes 32 hospital and practice member institutions staffed by hundreds of oncology researchers and physicians from around the globe. Dr. Knudsen is an expert in the molecular basis of hormone-dependent cancer development and progression, with a special focus on developing means to prevent or treat lethal prostate cancers. Dr. Knudsen’s research interests are dedicated to understanding the mechanisms by which genetic alterations lead to cancer progression and therapeutic bypass. Her studies identifying tumor suppressor and hormone receptor alterations have uncovered new targets for treating advanced disease, and led to development of innovative, biomarker-driven clinical trials. Dr. Knudsen is the Hilary Koprowski Professor and Chair of Cancer Biology at the Thomas Jefferson University, with joint appointments in the Departments of Urology, Radiation Oncology, and Medical Oncology. Notably, Dr. Knudsen served as the first Vice Provost for Thomas Jefferson University, overseeing and integrating basic and clinical research across all six schools at TJU. She took leave of this post in light of her appointment as Director of the Sidney Kimmel Cancer Center (SKCC). For the NCI-designated center, Dr. Knudsen was appointed in 2015 as Director. Dr. Knudsen has significant experience leading multidisciplinary efforts at SKCC and beyond, having served as Deputy Director for Research, founding Leader of the Prostate Program, and Director of Research for t Medical Oncology. Dr. Knudsen serves on multiple national boards and committees associated with both basic and clinical research, including several for the American Association for Cancer Research, the Endocrine Society, and the Prostate Cancer Foundation. She was a Senior Editor for Cancer Research from 2007-2013, is an Associate Editor for Endocrine-Related Cancer, and sits on the editorial boards of Molecular Cancer Therapeutics, the American Journal of Pathology, Molecular Endocrinology, and Oncogene. Most recently, Dr. Knudsen was appointed Editor-in-Chief of Molecular Cancer Research by AACR.
Advancing Innovative Therapeutic Approaches

Key Opinion Leaders and leading Industry-focused Investors who leverage their talent, influence and capital to identify and grow businesses will share their depth of knowledge, insights and outlook.

Gastroenterology

  • Scott Waldman, MD, PhD, is Program Director, Professor and Chair of the Department of Pharmacology and Experimental Therapeutics at Sidney Kimmel Medical College. His research focuses on GCC, demonstrating the importance of this receptor as a novel tumor suppressor central to the induction of colorectal cancer, and the translation of those observations to patient care. Indeed, he is the PI of NCI multi-institutional clinical trials examining the utility of GCC as a molecular marker for managing patients with, and as a target for the prevention of, colorectal cancer. Projects in his laboratory examine the translation of GCC biology into approaches to image colorectal tumors, prevent neoplastic transformation in intestine, and paradigms for vaccine development for patients with colorectal cancer. His research combines both basic and clinical investigation and serves as an exemplar of translational research. Dr. Waldman’s office is 901 College.

 

Immunology

  • Christine Eischen, PhD, is Professor and Special Advisor to the President of Thomas Jefferson University Hospitals. The primary focus of  Eischen Laboratory is on tumor initiation. Eischen lab wants to know how does a normal cell become a cancer cell. Specifically, Eischen lab wants to know what are the genes and pathways that contribute to or inhibit cellular transformation. Eischen lab studies the pathways, proteins, and recently, the miRNA and lncRNA that contribute to or inhibit tumor development with emphasis on the oncogenes Myc and Mdm2. B cell lymphoma is the cancer that we have almost 2 decades of experience studying, and multiple projects utilize this expertise. However, lung, breast, and ovarian carcinomas and cutaneous T cell lymphomas are also studied in the lab. Research in the Eischen lab spans from basic science with and without mouse models through translational research with patient material and bioinformatics.

Oncology

  • Les Funtleyder is an Adjunct Professor of Public Health at Columbia. He is also Portfolio Manager of E Squared Asset Management, an accomplished family office targeting emerging growth companies with potentially disruptive technologies or services. Les =is an experienced healthcare investor and analyst with a track record of significant positive returns across Pharmaceuticals, Medical Technology, Managed Care, Hospitals and other facilities, and Healthcare Information Technology utilizing public equity, private equity and debt. He has served as a speaker and resource to media, policymakers and corporations on the intersection of investing, health policy and innovation. Les is the author of Healthcare Investing: Profiting from the New World of Pharma, Biotech, and Health-Care Services (McGraw Hill, 2009).

 

 
Rare Disease

  • Sergei Petukhov, PhD, is a Partner of Enso Ventures, a private investment company that specializes in making selective investments in Europe and the USA. The company focuses on two distinct fields: materials-technology and biotechnology. The flexibility of the company’s structure and its hands-on approach means it can invest in a wide array of opportunities. The family office harnesses its industry expertise, leadership and capital in order to commercially develop and accelerate technologies in start-up companies. Dr. Sergei Petukhov is a Partner of Enso Ventures. Dr. Petukhov was a Managing Director at CLS Capital, he worked at RUSNANO investment fund and was an advisor at Kaye Scholer LLP for number of US pharmaceutical companies. Dr. Petukhov led Enso biotechnology investments and took several board observer positions at Enso portfolio companies including Seres Therapeutics, Galera Therapeutics and Cellectar Biosciences. Dr. Petukhov worked and studied at The Rockefeller University, The University of Edinburgh, The University of Cambridge and Moscow 1st Medical Academy.
The Wonder Plant of the Century

A leader in innovation, Thomas Jefferson University is dedicated to embracing the ever-evolving nature of healthcare and researching new cutting-edge methods for the treatment of diseases. In 2016, Jefferson became the first health sciences university in the nation to provide groundbreaking resources and support for the study of medical marijuana. Jefferson’s Dr. Pollack who leads Jefferson’s Center for Medical Cannabis Education & Research (CMCER) will discuss his views on new approaches to illness management and pain relief with two business leaders who have invested heavily in the research and development of a wonder plant proven to advance the health of humankind.

  • Barry Lambert, Chairman of Countplus, a professional services aggregation network of 18 businesses across Australia. Barry established Count Financial in 1980. Prior to establishing Count, Barry worked for 19 years within the Commonwealth Bank of Australia. Barry was a Founding Director of the industry body ASIFA (now the FPA) in 1982 and was elected NSW President in 1985 and National President of ASIFA in 1988. Barry is the Chairman of the CBA part owned Countplus Limited and a Director of many Countplus Member Firms. He is also the founder and Director of the Count Charitable Foundation. Outside of the Countplus group, Barry is also the Chairman of the Class Super companies, a rapidly growing cloud based IT software solutions business specializing in Self-Managed Superannuation Funds administration.
  • Kevin McGovern, Chairman and CEO of McGovern Capital and The Water Initiative®, which co-creates customized and sustainable drinking water solutions through innovative partnerships with municipalities, business and local microentrepreneurs in developing and developed countries. Through McGovern Capital, he has founded over fifteen companies, six of which have become world/category leaders, has been lead negotiator/principal in over twenty (20) global joint ventures. McGovern Capital serves as an investment, strategy and  licensing participant and advisor to global businesses. McGovern was a founder of  SoBe Beverages, the fastest growing beverage company ever in the US (sold to Pepsi), and McGovern Capital was one of three owners of KX Industries, L.P., the largest manufacturer and worldwide source of carbon water purification filters, having invented and supplied PUR to P&G, the first end-of-tap filter to Brita, and the first refrigerator water filter to Electrolux. He also created the program, supervised and negotiated all licensing of Tristrata’s alpha hydroxy acid (AHA) patents, which technology was incorporated in approximately 40% of all global skin care products, and is sold in approximately 88 countries. He serves/served on many public and private boards including The Sports Authority (Exec. Committee – NYSE).
  • Charles V. Pollack, Jr., MA, MD, FACEP, FAAEM, FAHA, FESC, FCPP, is Director of the Lambert Center for the Study of Medicinal Cannabis and Hemp; Associate Provost for Innovation in Education; Director of the Institute of Emerging Health Professions; Associate Dean for CME and Strategic Partner Alliances; and, Professor and Senior Advisor for Interdisciplinary Research and Clinical Trials, Department of Emergency Medicine, Sidney Kimmel Medical College at Thomas Jefferson University. From 2001-2015, Dr. Pollack was Professor of Emergency Medicine at the Perelman School of Medicine of the University of Pennsylvania and served as Chairman of Emergency Medicine at Pennsylvania Hospital in Philadelphia. He graduated summa cum laude from Emory University in 1980 with BA degrees in history and chemistry and with an MA in the history of science and medicine. He was elected to Phi Beta Kappa. Dr. Pollack earned his medical degree from Tulane University School of Medicine and is a member of Alpha Omega Alpha. Dr. Pollack has long been active in teaching and clinical research and is an international leader in emergency medicine. He is the only physician to have received the American College of Emergency Physicians’ highest national awards in both teaching and research, and in 2015 became the first US emergency physician to be elected a Fellow of the European Society of Cardiology (FESC). Dr. Pollack has written more than 500 original research articles, chapters, and abstracts, and serves on the editorial boards of several journals and on the steering committees of multiple national and international trials. Dr. Pollack also lectures widely on many varied topics in emergency medicine. He is a strong advocate for entrepreneurism and innovation in healthcare. He is a founding Board member of the Hospital Quality Foundation, a non-for-profit organization dedicated to improvement in the quality of care provided in the hospital and at transition back to the outpatient setting.
Why Social Impact Investing is the New Frontier

“Have we the nerve and the will? Can we carry through in an age where we will witness not only new breakthroughs in weapons of destruction, but also a race for mastery of the sky and the rain, the ocean and the tides, the far side of space, and the inside of men’s minds? That is the question of the New Frontier.” – President John F. Kennedy

The Kennedy family has been involved with Health Care innovation since the 1940’s. The family endowed the Chair of Neuroscience at Harvard Medical School, founded the National Center for Children and Families at the National Institute of Health (NIH), and created the Special Olympics, among other things. Ted Kennedy was responsible for overseeing funding for US healthcare research for 40 years, and the family has an unparalleled network of contacts in academic medical centers nationwide. In addition, the family founded two of the largest and most influential nonprofits in neuroscience and health care policy innovation – The Kennedy Forum and One Mind for Research – and founded two successful health care businesses – MEDCO, the nation’s first Plan Benefit Manager, and The Marwood Group, a premier health care regulatory and reimbursement risk consulting firm. New Frontier Bio, a holding company co-founded by Stephen Kennedy Smith and Corey McCann, leverages the long-term involvement of the Kennedy family in health care and academia to identify and commercialize transformative medical innovations that have the potential to achieve early stage validation, transform millions of lives, and become highly valuable businesses.

  • Stephen Kennedy Smith is a principal at Park Agency – Joseph P. Kennedy Enterprises, the Kennedy family office, and an investor and entrepreneur. He has served as a director or advisor to several companies, including Gridline Communication Holdings, Pear Therapeutics, Owl Biomedical, and LocoMobi. His current investment and business focus is scaling innovative healthcare, and neuroscience companies. Stephen is a board member of the John F. Kennedy Library and The Joseph P. Kennedy Foundation. He also serves on the advisory board at INCAE Business School. He is cofounder and vice president of the World Leadership Alliance, an organization of business and political leaders that promotes, democracy, international understanding and trade. Stephen is currently a lecturer at the Sloan school of Management in the visionary investing program, as well as a fellow at the Connection Science Group at MIT. He holds an M.A. from Harvard University, a J.D. from Columbia University, and an M.A. Ed. from Harvard’s School for Education. He has served on the staff of the Senate Judiciary and Foreign Relations Committees and is a three-time recipient of the Danforth Award for Excellence in Teaching at Harvard University.
  • Corey McCann, MD, PhD has background as a physician, scientist, entrepreneur, and healthcare investor. Previously, he was an investor with MPM Capital and with RiverVest Venture Partners, where he evaluated new investment opportunities, managed relationships with strategic partners, and oversaw board-level strategy and execution at portfolio companies. Prior to MPM, he was with McKinsey & Company, where he advised pharmaceutical, medical device, and biotechnology companies on the acquisition, development, and commercialization of life science technologies. He also led McKinsey’s Central Nervous System (CNS) expertise group, serving clients across pharma and biotech. He is a founding member of multiple start-ups including Alcyone Lifesciences, a company developing technologies to deliver therapeutics to the brain. Dr. McCann’s post-graduate training was at Harvard University, Washington University in St Louis, and at the Massachusetts General Hospital, and he graduated summa cum laude from The Pennsylvania State University where he was an Evan Pugh Scholar.
The Future of Clinically Integrated Networks

Jefferson University Hospitals and Thomas Jefferson University are partners in providing excellent clinical and compassionate care for our patients in the Philadelphia region, educating the health professionals of tomorrow in a variety of disciplines and discovering new knowledge that will define the future of clinical care. Jefferson has topped the list of hospitals in Pennsylvania (3rd) and the Philadelphia metro area (2nd) in U.S.News & World Report’s annual listing of the best hospitals and specialties.

  • Stephen K. Klasko, MD, MBA, is President and CEO of Philadelphia-based Thomas Jefferson University, a regional healthy system of hospitals dedicated to the health sciences and committed to educating professionals, discovering new knowledge, and setting the standard for quality, compassionate and efficient patient care. What began as Jefferson Medical College in 1824, now known as Sidney Kimmel Medical College, has grown into one of the nation’s leading healthcare learning institutions. Dr. Klasko has championed transformation of American health care as university president, dean of two medical colleges, and CEO of three academic health centers. He is author of 2016’s We CAN Fix Healthcare in America, and editor in chief of “Healthcare Transformation.” Since 2014, Jefferson Health has grown from a three hospital urban academic medical center with annual revenues of $1.8 billion to a major regional academic medical center. Currently an eight-hospital system, resulting from the merger of Jefferson with Abington Health, Jefferson Health will expand to an 11-hospital system with the proposed partnership mergers with Aria Health and Kennedy Health. Jefferson has the largest tele-health network in the region, the NCI-designated Sidney Kimmel Cancer Center, and an outpatient footprint that is among the most technologically advanced in the region. Upon completion of the proposed merger with Philadelphia University — creating a comprehensive university with a forward-thinking education model — Jefferson will have combined annual revenues exceeding $4.8 billion, more than 28,000 employees, 7,800 students, 6,000 physicians/practitioners and 4,000 faculty.
The Next Giant Leap: Making the Cancer Moonshot a Reality
  • David Ahern is Special Advisor, Health Communications and Informatics Research Branch (HCIRB) of the National Cancer Institute (NCI). The NCI is part of the National Institutes of Health (NIH), which is one of 11 agencies that compose the Department of Health and Human Services (HHS). The NCI, established under the National Cancer Institute Act of 1937, is the Federal Government’s principal agency for cancer research and training. The National Cancer Act of 1971 broadened the scope and responsibilities of the NCI and created the National Cancer Program. Over the years, legislative amendments have maintained the NCI authorities and responsibilities and added new information dissemination mandates as well as a requirement to assess the incorporation of state-of-the-art cancer treatments into clinical practice. The National Cancer Institute coordinates the National Cancer Program, which conducts and supports research, training, health information dissemination, and other programs with respect to the cause, diagnosis, prevention, and treatment of cancer, rehabilitation from cancer, and the continuing care of cancer patients and the families of cancer patients. David K. Ahern, Ph.D., is on special assignment to the National Cancer Institute under an Intergovernmental Personnel Act (IPA) whereby he serves as a special advisor to both the Health Communications and Informatics Research Branch and the Healthcare Delivery Research Branch within the Behavior Research Program. In this role he assists the chief and staff of both branches in developing a research agenda in health and behavioral informatics to enable enhanced care across the cancer care continuum.
A New Modality of Patient Care: Supporting the Caregiver & Extending the Clinical Setting into the Home
Innovations in Population Health
  • David Nash, MD, is Founding Dean, The Raymond C. and Doris N. Grandon Professor of Health Policy of the Jefferson College of Population Health, the first College of its kind in the country! Established in 2008, the College is part of Thomas Jefferson University, a leading academic health center founded in Philadelphia, PA in 1824 as Jefferson Medical College (now the Sidney Kimmel Medical College). The College is dedicated to exploring the policies and forces that define the health and well-being of populations. The mission of the College is to prepare leaders with global vision to examine the social determinants of health and to evaluate, develop and implement health policies and systems that will improve the health of populations and thereby enhance the quality of life. The College achieves this by providing exemplary graduate academic programming in population health, public health, health policy, healthcare quality and safety, and health outcomes research. The College’s educational offerings are enhanced by research, publications and continuing education and professional development offerings in these areas. David B. Nash, MD, MBA was named the Founding Dean of the College in 2008. This appointment caps a 25 year tenure on the faculty of Thomas Jefferson University. Dr. Nash is a board certified internist who is internationally recognized for his work in public accountability for outcomes, physician leadership development, and quality-of-care improvement. Repeatedly named to Modern Healthcare’s list of Most Powerful Persons in Healthcare, his national activities cover a wide scope. Through publications, public appearances, his “Nash on the Road” blog, and an online column on MedPage Today, Dr. Nash routinely reaches more than 100,000 persons every month. He has authored more than 100 articles in major peer-reviewed journals. He has edited 23 books, including Connecting with the New Healthcare Consumer, The Quality Solution, Population Health: Creating a Culture of Wellness, and most recently, Demand Better. Currently, he is Editor-in-Chief of four major national journals including American Journal of Medical Quality, Population Health Management, P&T, and American Health and Drug Benefits (AHDB).
The Power of Compassion

“… the remarkable story of a neurosurgeon’s quest to unravel the mystery of the link between our brains and our hearts. From the moment in his childhood when a simple act of kindness changed the course of his own life to his founding a center to study compassion at Stanford University. Jim Doty’s life illustrates how each of us can make a difference. We can make the world a more compassionate place. I’m sure many readers will be moved by this inspiring story to open their hearts and see what they too can do for others.” – His Holiness the Dalai Lama

Linking Health and the Importance of a Clean and Safe Environment

Challenges that threaten humanity’s health require innovative responses and insights. The power of collaboration can ensure a prosperous future. Experts discuss the nature of the challenges we face today, and how to respond to and contain these threats.

  • Jonathan Granoff, President of Global Security Institute, is a former professor of international law, and serves as a Senior Advisor and Special Representative to the United Nations for the Permanent Secretariat of the World Summit of Nobel Peace Laureates. He is the Chair of the Task Force on Nuclear Nonproliferation of the International Law Section of the American Bar Association, and Ambassador for Peace and Security of the Parliament of the World’s Religions. He focuses his advocacy efforts on the legal, moral, political and spiritual dimensions of peace with a particular emphasis on the rule of law and the elimination of nuclear weapons. He serves on numerous advisory and governing boards such as the NGO Committee on Disarmament, Peace and Security at the UN, Lawyers Committee on Nuclear Policy, Middle Powers Initiative, Parliamentarians for Nuclear Nonproliferation and Disarmament, and the Jane Goodall Institute. He is a Fellow in the World Academy of Arts and Science and recipient of numerous awards such as the Arthur E. Armitage, Sr. Distinguished Alumni Award of Rutgers University School of Law. Mr. Granoff is the award-winning screenwriter of The Constitution: The Document that Created a Nation, and has articles in more than 50 publications and books including: The Sovereignty Revolution, Toward a Nuclear Weapons Free World, Imagining Tomorrow, Analyzing Moral Issues, Perspectives on 911, Toward a World In Balance, Reverence for Life Revisited, and Hold Hope, Wage Peace. He has been a featured guest and expert commentator on hundreds of radio and television programs, and testified as an expert in the US Congress, Parliaments of the UK and Canada, and at the UN numerous times. He has represented the Nobel Laureate organization the International Peace Bureau at Nobel Laureate Summits and was nominated for the Nobel Peace Prize in 2014.
Healthy Role Models for Kids

Become a Sponsor of The Great Red Clay Wellness Challenge, and show your support of wellness and education-related initiatives for Red Clay schools!

The Red Clay Consolidated School District recognizes that student wellness and proper nutrition are related to students’ physical well-being, growth, development and readiness to learn. In a healthy school environment, students learn about and participate in positive dietary and lifestyle practices that can improve student achievement. It is the policy of the District to encourage healthy lifestyle habits for all members of the school community: children, parents, and staff.

Every day 18,000 students pass through the doors of the Red Clay Consolidated School District. By supporting The Great Red Clay Wellness Challenge, you will inspire thousands of kids to shape up, have fun and make wellness a top priority.

Over the course of 10 weeks, Red Clay schools and offices will compete as teams to get in shape. The team that loses the greatest percentage of weight wins a $500 grand prize to support wellness or education-related initiatives in their building.

“Every accomplishment starts with the decision to try.”

For sponsorship details of The Great Red Clay Wellness Challenge, please contact Taylor Green, Office of the Deputy Superintendent.

 
 
Philanthropy

Shot@Life, campaign of the United Nations Foundation, aims to ensure that children around the world have access to life-saving vaccines. Through education, advocacy, and fundraising we strive to decrease vaccine-preventable childhood deaths and give every child a shot at a healthy life no matter where they live.

 

  • Martha Rebour joined the United Nations Foundation in 2014. She serves as Senior Director of Shot@Life, a global campaign to increase access to immunizations for children in need through UN partners. She oversees its marketing, communications, corporate partnerships, and brand strategy. Martha has more than 15 years of experience in strategic branding,social media marketing, creative development and consumer research for corporate and nonprofit organizations. Prior to joining the UN Foundation she worked for 10 years at Discovery Communications and oversaw marketing campaigns such as the 20th Anniversary of Shark Week, the BBC series LIFE and Mythbusters, and subsequently ran her own marketing firm where she directed strategic planning and marketing for clients such as the InterAmerican Development Bank, Ogilvy Public Relations, National Geographic, and PBS. She holds a B.A. from Colby College and an MA in French language from New York University.

 
Shot@Life

 

 
Jefferson is a powerful institution with a singular goal: to improve human health. What happens each day in Jefferson’s classrooms, clinics and laboratories inspires the support of generous donors looking for the highest possible return on their philanthropic investments. The purpose of the Jefferson Office of Institutional Advancement is to seek, acquire and manage charitable contributions from individuals, organizations, corporations and foundations to advance Jefferson’s mission of clinical care, education and discovery by:

  • Improving the health of our patients, families and community
  • Providing unrestricted funds to meet the most urgent needs
  • Supporting research programs
  • Strengthening our faculty to maintain academic excellence
  • Growing the capabilities and impact of academic departments
  • Providing scholarship assistance for students
  • Initiating new programs that reinvent health sciences education
  • Enlarging the pool of endowed funds to secure Jefferson’s future

 

  • Jonathan Agree, Associate Vice President of Development for the Sidney Kimmel Cancer Center and Clinical Programs at Thomas Jefferson University, joined the Office of Institutional Advancement in 2014. Previously, he was a major gifts officer at Fox Chase Cancer Center. He earned a Bachelor of Arts from Temple University.

 

Thomas Jefferson University Hospital

Venue

 
Thomas Jefferson University – Dorrance H. Hamilton Building
Address: 925 Chestnut St # 220A, Philadelphia, PA 19107
Phone: (215) 955-8874

 
 

Independence Hall
The Liberty View

Address: Independence Visitor Center, 599 Market St, Philadelphia, PA 19106
Phone: (215) 965-2300

 

In his speech at Independence Hall on July 4, 1962, President John F. Kennedy praises the American democratic system which encourages differences and allows for dissent, discusses the enduring relevance of the Constitution and the Declaration of Independence, and addresses the role of the United States in relation to the emerging European Community.

 

Stephen Kennedy Smith will give a fresh take on the relevance of his uncle’s words today, JFK’s life and presidency, and his compelling vision for America.

In commemoration of the centennial of JFK’s birth, Stephen authored “JFK: A Vision for America” (release on May 2, 2017), the definitive compendium of JFK’s most important and brilliant speeches, accompanied by commentary and reflections by leading American and international figures – including Senator Elizabeth Warren, David McCullough, Kofi Annan, and the Dalai Lama — and edited by JFK’s nephew Stephen Kennedy Smith and renowned historian Douglas Brinkley. Combined with over seven hundred documentary photos, it tells the story, in words and pictures, of JFK’s life and presidency, and depicts his compelling vision for America. The august list of contributors includes Secretary John Kerry, Ambassador Samantha Power, Congressman John Lewis, Senator John McCain, Senator Elizabeth Warren, His Holiness the 14th Dalai Lama, Robert Redford, Conan O’Brien, Dave Eggers, Gloria Steinem, Don DeLillo, David McCullough, George Packer, Colum McCann, Michael Beschloss, Robert Dallek, David Kennedy, Ted Widmer, Henry Louis Gates Jr., Drew Faust, Tariq Ramadan, Pastor Rick Warren, Jonathan Alter, E. J. Dionne, Ron Suskind, Paul Krugman, Kofi Annan, Governor Jerry Brown, Paul Theroux, Jorge Domínguez, and many others.

  • Stephen Kennedy Smith is a principal at Park Agency – Joseph P. Kennedy Enterprises, the Kennedy family office, and an investor and entrepreneur. He has served as a director or advisor to several companies, including Gridline Communication Holdings, Pear Therapeutics, Owl Biomedical, and LocoMobi. His current investment and business focus is scaling innovative healthcare, and neuroscience companies. Stephen is a board member of the John F. Kennedy Library and The Joseph P. Kennedy Foundation. He also serves on the advisory board at INCAE Business School. He is cofounder and vice president of the World Leadership Alliance, an organization of business and political leaders that promotes, democracy, international understanding and trade. Stephen is currently a lecturer at the Sloan school of Management in the visionary investing program, as well as a fellow at the Connection Science Group at MIT. He holds an M.A. from Harvard University, a J.D. from Columbia University, and an M.A. Ed. from Harvard’s School for Education. He has served on the staff of the Senate Judiciary and Foreign Relations Committees and is a three-time recipient of the Danforth Award for Excellence in Teaching at Harvard University.
 
Agenda
       
START END      
8:00 AM 9:00 Breakfast
9:00 12:00 PM Tour of Longwood Gardens
12:00 1:00 Lunch
2:00 5:00 Historic Walking Tour
6:30 9:30 Dinner
       
START END      
8:00 AM 9:00 Breakfast
9:00 12:00 PM Spa or Please Touch Museum
12:00 2:00 Lunch
2:00 5:00 The Barnes Foundation - Private Museum Tour
     
     
     
     
6:00 6:30 ICV Philadelphia - Welcome Remarks by Stephen Kennedy Smith - "JFK: A Vision for America"
6:30 7:00  Musical Performance
7:00 9:00 Dinner Reception
08:00 AM Breakfast
START END
General Session
9:00 9:30  
9:30 10:00  
10:00 10:15  
10:15 10:45  
10:45 11:15  
11:15 11:30  
11:30 12:00 PM  
12:00 12:30  
12:30 2:00  Networking Luncheon
2:00 2:30  
2:30 3:00  
3:00 3:30  
3:30 4:00  
4:00 4:30  
4:30 5:00  
5:00 6:30 Networking Reception
06:30 PM Private Company Dinner  Public Company Dinner  
START END
Presenting Companies

Presenting Companies
 
6:30 6:45 Welcome Remarks by Dr. Stephen Klasko, President and CEO of Thomas Jefferson University
6:45 7:00 Company Presentation Company Presentation
7:00 7:15 Q & A Q & A
7:15 7:30 Company Presentation Company Presentation
7:30 7:45 Q & A Q & A
7:45 8:00 Company Presentation Company Presentation
8:00 8:15 Q & A Q & A
8:15 8:30 Company Presentation Company Presentation
8:30 8:45 Q & A Q & A
8:45 9:00  Guest Speaker
9:00 9:30  Musical Performance
9:40 10:00 Shuttle Services